Valuation: ALLOVIRPAR

Market Cap 49.21M 43.02M 39.54M 36.85M 69.9M 4.69B 70.96M 475M 185M 2.3B 185M 181M 7.94B P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -69.08M -60.39M -55.5M -51.73M -98.12M -6.58B -99.6M -666M -259M -3.23B -259M -254M -11.14B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day+4.86%
Current month-51.58%
Current year-51.58%
3 years 4.38
Extreme 4.38
87.17
5 years 4.38
Extreme 4.38
607.43
10 years 4.38
Extreme 4.38
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -166M -153M -143M -270M -18.13B -275M -1.84B -714M -8.91B -715M -699M -30.71B -58.77M -51.38M -47.21M -44.01M -83.47M -5.6B -84.74M -567M -220M -2.75B -221M -216M -9.48B
Net Debt -157M -137M -126M -117M -222M -14.9B -226M -1.51B -587M -7.33B -587M -575M -25.24B -118M -103M -95.03M -88.58M -168M -11.26B -171M -1.14B -444M -5.54B -444M -434M -19.08B
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change Volume
26-07-02 US$4.750 +4.86% 56,292
26-07-01 US$4.530 +11.30% 54,459
26-06-30 US$4.070 -3.44% 104,019
26-06-29 US$4.215 -2.43% 122,083
26-06-26 US$4.320 +0.47% 164,531
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock